GLAXO WELLCOME DECIDES TO WITHDRAW LOTRONEX FROM THE MARKET

The following information is available on Lotronex

Submit your claim for review.

The FDA announcement is here.
Glaxo Wellcome, of Research Triangle Park, NC, has informed FDA that it will voluntarily withdraw Lotronex (alosetron hydrochloride) tablets from the market.

La Times Story.
An FDA medical officer, Dr. John R. Senior, discovered during the review that four Lotronex patients in clinical studies suffered a potentially life-threatening complication called ischemic colitis, which results from inadequate blood flow to the colon.

Irritable Bowel Syndrome (IBS).
Irritable bowel syndrome (IBS) is a common but poorly understood disorder that causes a variety of bowel symptoms including abdominal pain, diarrhea and/or constipation, bloating, gassiness and cramping.

FDA re-examines Lotronex.
"Why continue to endanger the health and lives of millions of people... until a 'sufficient' number of hospitalizations and further deaths occur for you to take action?"